Ray Dalio's BCRX Position Overview
Ray Dalio (via Bridgewater Associates, Lp) currently holds 235,572 shares of BioCryst Pharmaceuticals, Inc. (BCRX) worth $1.84 M, representing 0.01% of the portfolio. First purchased in 2025-Q3, this recently established position has been held for 2 quarters.
Based on recent 13F filings, Ray Dalio has initiated a new position in BCRX, representing a fresh investment thesis on this company. Largest reduction occurred in Q4 2025, reducing 175,931 shares.
Analysis based on 13F filings available since 2013 Q2
Ray Dalio's BioCryst Pharmaceuticals (BCRX) Holding Value Over Time
Track share changes against reported price movement
Quarterly BioCryst Pharmaceuticals (BCRX) Trades by Ray Dalio
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q4 2025 | -175,931 | Reduce 42.75% | 235,572 | $7.80 |
| Q3 2025 | +411,503 | New Buy | 411,503 | $7.59 |
Ray Dalio's BioCryst Pharmaceuticals Investment FAQs
Ray Dalio first purchased BioCryst Pharmaceuticals, Inc. (BCRX) in Q3 2025, acquiring 411,503 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Ray Dalio has held BioCryst Pharmaceuticals, Inc. (BCRX) for 2 quarters since Q3 2025.
Ray Dalio's largest addition to BioCryst Pharmaceuticals, Inc. (BCRX) was in Q3 2025, adding 411,503 shares worth $3.12 M.
According to the latest 13F filing for Q4 2025, Ray Dalio's firm, Bridgewater Associates, Lp, owns 235,572 shares of BioCryst Pharmaceuticals, Inc. (BCRX), valued at approximately $1.84 M.
As of the Q4 2025 filing, BioCryst Pharmaceuticals, Inc. (BCRX) represents approximately 0.01% of Ray Dalio's publicly disclosed stock portfolio, making it one of their key holdings.
Ray Dalio's peak holding in BioCryst Pharmaceuticals, Inc. (BCRX) was 411,503 shares, as reported at the end of Q3 2025.